chikungunya
viru
chikv
infect
million
peopl
africa
europ
sinc
reemerg
kenya
sever
diseas
spread
epidem
viru
present
seriou
public
health
threat
absenc
vaccin
antivir
therapi
describ
novel
vaccin
protect
emerg
chikv
infect
nonhuman
primat
nhp
show
select
express
viral
structur
protein
give
rise
viruslik
particl
vlp
vitro
resembl
replicationcompet
alphavirus
immun
vlp
elicit
neutral
antibodi
envelop
protein
differ
chikv
strain
monkey
immun
vlp
produc
high
titer
neutral
antibodi
protect
viremia
high
dose
challeng
transfer
antibodi
immunodefici
mice
protect
subsequ
lethal
chikv
challeng
establish
humor
mechan
protect
immun
alphaviru
vlp
vaccin
repres
strategi
contain
spread
chikv
relat
pathogen
virus
human
chikungunya
viru
chikv
mosquitoborn
alphaviru
famili
togavirida
first
isol
tanzania
infect
viru
human
character
rash
high
fever
hallmark
featur
sever
arthriti
persist
epidem
strain
chikv
appear
reunion
island
sinc
spread
see
also
http
wwwcdcgovncidoddvbidchikungunya
chglobalmaphtml
dissemin
epidem
viru
associ
genet
mutat
facilit
adapt
new
insect
vector
asian
tiger
mosquito
aed
surviv
temper
climat
wide
chikv
continu
caus
substanti
morbid
result
signific
econom
loss
vaccin
develop
remain
high
prioriti
chikv
compos
posit
singl
strand
genom
rna
nucleotid
encod
four
nonstructur
five
structur
nonstructur
protein
requir
viru
replic
structur
protein
consist
capsid
c
envelop
protein
e
synthes
polyprotein
cleav
capsid
autoproteinas
fig
upper
panel
base
similar
chikv
alphavirus
chikv
spike
virion
surfac
form
three
glycoprotein
mediat
fusion
glycoprotein
interact
host
phylogenet
analysi
chikv
reveal
three
genotyp
asian
eastcentralsouth
african
west
african
strain
highli
relat
amino
acid
although
chikv
strain
vari
individu
strain
antigen
relat
potenti
possibl
design
vaccin
work
heterolog
first
analyz
immunogen
crossreact
two
dispar
strain
older
west
africa
lineag
recent
strain
respons
current
epidem
examin
specif
viral
cell
entri
sensit
neutral
antibodi
develop
lentivir
vector
report
pseudotyp
glycoprotein
differ
chikv
strain
vector
allow
analysi
mechan
specif
entri
serv
quantit
antibodi
neutral
readili
wild
type
virus
pose
signific
biohazard
concern
routin
laboratori
analys
therefor
provid
use
tool
studi
chikv
entri
well
vaccin
insert
chikv
e
gene
express
nativ
polypeptid
fig
lower
panel
strain
express
vector
e
e
incorpor
two
chikv
es
pseudotyp
lentivir
vector
verifi
buoyant
densiti
gradient
sediment
viru
chikv
e
gag
buoyant
densiti
lentiviru
particl
supplementari
fig
chikv
pseudotyp
lentivir
vector
infect
sever
cell
line
permiss
viral
fig
left
measur
abil
express
luciferas
report
human
renal
epitheli
cell
found
entri
dosedepend
fig
right
control
devoid
chikv
envelop
protein
infect
cell
line
determin
whether
entri
occur
mechan
nativ
viru
analyz
ph
endosom
depend
entri
chikv
infect
phdepend
cell
thu
addit
ammonium
chlorid
chloroquin
prevent
acidif
endosom
caus
dosedepend
reduct
chikv
pseudotyp
vector
entri
fig
observ
similar
inhibit
entri
vsvg
known
enter
fashion
amphotrop
murin
leukemia
viru
mulv
glycoprotein
enter
phindepend
find
demonstr
lentivir
vector
pseudotyp
chikv
envelop
mediat
entri
mechan
wild
type
viru
next
examin
commerci
avail
immun
serum
mice
infect
establish
chikv
strain
atcc
incub
immun
sera
chikv
pseudotyp
lentivir
vector
vsvg
pseudotyp
vector
inhibit
entri
fig
specif
potenc
neutral
antibodi
could
therefor
quantifi
without
exposur
infecti
viru
analyz
eukaryot
express
vector
encod
strain
ce
ce
abil
give
rise
vlp
transfect
human
kidney
cell
plasmid
ce
ce
e
express
vector
describ
e
e
fig
upper
panel
confirm
express
cell
lysat
western
blot
fig
lower
panel
also
detect
c
protein
supernat
western
blot
transfect
ce
ce
vector
suggest
chikv
vlp
gener
purifi
vlp
buoyant
densiti
gradient
sediment
yield
vlp
strain
mg
l
approxim
time
higher
strain
reason
high
degre
amino
acid
similar
among
chikv
strain
use
strain
produc
vlp
fraction
clarifi
supernat
show
greatest
incorpor
vlp
densiti
g
ml
fig
left
compar
densiti
wild
type
examin
purifi
fraction
strain
electron
microscopi
reveal
vlp
morpholog
appear
wild
type
viru
fig
right
cryoelectron
microscopi
three
dimension
imag
reconstruct
assum
icosahedr
symmetri
show
vlp
extern
diamet
nm
core
diamet
nm
fig
potent
immunogen
glycoprotein
organ
heterodim
assembl
glycoprotein
spike
arrang
quasi
symmetri
surfac
vlp
fig
close
similar
structur
sindbi
viru
supplementari
fig
see
also
ref
eas
dna
vaccin
prepar
broad
applic
compar
rel
immunogen
plasmid
dna
vlp
vaccin
mice
immun
dna
vaccin
encod
ce
e
strain
vlp
strain
vlp
presenc
absenc
ribi
adjuv
balbc
mice
inject
twice
intramuscularli
vlp
adjuv
gener
highest
titer
neutral
respons
homolog
strain
fig
right
panel
ic
heterolog
strain
fig
right
panel
ic
three
immun
plasmid
encod
ce
e
strain
elicit
neutral
respons
titer
less
five
percent
vlpimmun
mice
fig
b
left
panel
ic
titer
dna
ce
strain
dna
ce
strain
result
suggest
vlp
elicit
potent
neutral
antibodi
respons
dna
vaccin
character
vlpinduc
immun
respons
model
stronger
predict
valu
human
immun
rhesu
macaqu
vlp
monkey
receiv
intramuscular
inject
vlp
pb
alon
control
test
sera
immun
control
monkey
chikv
strain
pseudotyp
lentivir
vector
nonhuman
primat
nhp
immun
vlp
develop
substanti
neutral
activ
homolog
heterolog
strain
primari
immun
increas
boost
fig
left
panel
ic
titer
strain
right
panel
ic
titer
strain
interestingli
slightli
increas
neutral
compar
mice
monkey
although
effect
substanti
suggest
may
present
common
epitop
immun
system
somewhat
better
confirm
antibodi
neutral
infecti
viru
perform
plaqu
reduct
neutral
test
prnt
chikv
antisera
immun
monkey
elicit
neutral
antibodi
respons
prnt
titer
fig
data
suggest
neutral
antibodi
use
pseudotyp
lentivir
vector
correl
prnt
assay
vlpimmun
monkey
gener
potent
neutral
antibodi
respons
chikv
establish
chikv
challeng
model
monkey
inject
two
rhesu
monkey
intraven
high
titer
viru
stock
viremia
commenc
h
last
least
h
challeng
monkey
peak
viremia
h
infect
supplementari
fig
similar
human
infect
nhp
result
viremia
lethal
addit
observ
similar
transient
acut
lymphopenia
proinflammatori
respons
measur
transient
neutrophilia
increas
monocyt
count
supplementari
fig
assess
abil
vlp
vaccin
protect
infect
intraven
challeng
monkey
immun
vlp
control
use
high
titer
viru
stock
week
final
immun
model
immun
monkey
control
challeng
viru
complet
fig
contrast
observ
viremia
control
monkey
inject
chikv
pilot
experi
similarli
monocyt
count
markedli
increas
control
monkey
day
challeng
remain
unchang
vaccin
monkey
fig
control
day
vs
p
vlp
day
vs
p
data
suggest
immun
protect
viremia
inflammatori
consequ
infect
defin
mechan
protect
anim
investig
whether
immun
igg
could
protect
lethal
challeng
use
adopt
transfer
model
previou
studi
shown
immunodefici
mice
defect
typei
interferon
signal
suscept
lethal
chikv
infect
display
patholog
manifest
provid
model
evalu
immun
mechan
protect
exampl
couderc
et
show
antibodi
play
import
role
protect
chikv
infect
passiv
transfer
igg
infect
human
model
intraven
transfer
purifi
total
igg
immun
control
monkey
mice
challeng
recipi
mice
intraderm
lethal
dose
h
later
recipi
purifi
igg
chikvimmun
monkey
demonstr
detect
viremia
challeng
complet
protect
lethal
fig
contrast
mice
receiv
purifi
igg
control
monkey
show
sever
infect
viremia
die
result
indic
humor
immun
respons
induc
chikv
vlp
confer
protect
chikv
infect
date
limit
success
develop
safe
effect
chikv
vaccin
live
attenu
chikv
vaccin
caus
transient
arthralgia
effort
includ
formalinkil
venezuelan
equin
encephalitischikv
chimer
live
attenu
consensusbas
dna
yet
proven
safe
effect
develop
safe
effect
chikv
vaccin
requir
addit
evalu
human
howev
safeti
efficaci
vlp
vaccin
gener
make
promis
candid
studi
vlp
known
highli
immunogen
elicit
higher
titer
neutral
antibodi
respons
subunit
vaccin
base
individu
vlp
authent
present
viral
spike
surfac
compon
repetit
array
effect
elicit
recognit
bcell
stimul
antibodi
recognit
lead
b
cell
signal
mhc
class
ii
upregul
facilit
gener
high
titer
specif
antibodi
vlp
virus
includ
hepat
b
viru
human
papillomaviru
elicit
high
titer
neutral
antibodi
respons
contribut
protect
immun
vaccin
describ
repres
first
use
recombin
vlp
prevent
infect
alphavirus
time
commerci
avail
vaccin
chikv
emerg
potenti
significantli
impact
spread
diseas
chang
trade
travel
global
climat
aid
spread
mosquito
speci
worldwid
may
potenti
caus
alphaviru
outbreak
approach
vaccin
develop
may
prove
use
alphavirus
increas
concern
includ
western
eastern
venezuelan
equin
enceph
virus
onyongnyong
viru
ross
river
viru
synthes
plasmid
encod
structur
polyprotein
c
strain
genbank
respect
previous
geneart
amplifi
plasmid
encod
polyprotein
pcr
use
sens
primer
antisens
primer
sens
primer
antisens
primer
insert
xbai
bamhi
site
clone
digest
fragment
xbaibamhi
insert
eukaryot
express
vector
ce
ce
e
e
cmvr
vector
compris
human
cmv
ie
enhancerpromot
r
region
contain
splice
donor
cmv
ie
splice
acceptor
bovin
growth
hormon
poli
signal
creat
lentivir
vector
express
glycoprotein
differ
chikv
strain
method
produc
recombin
lentivir
vector
express
luciferas
report
gene
previous
briefli
cotransfect
cell
ng
chikv
e
plasmid
either
strain
e
e
transduc
vector
encod
luciferas
report
gene
control
cmv
promot
phrcmvluciferas
plasmid
packag
plasmid
express
human
immunodefici
viru
type
structur
protein
except
envelop
supplementari
fig
addit
method
neutral
assay
chikv
e
pseudotyp
lentivir
vector
describ
supplementari
method
transfect
cell
invitrogen
transfect
reagent
invitrogen
ce
plasmid
follow
manufactur
recommend
detail
method
buoyant
densiti
gradient
analysi
purif
vlp
describ
previou
supplementari
method
flashfroz
chikungunya
vlp
holey
grid
liquid
ethan
record
imag
magnif
feg
microscop
electron
dose
level
approxim
e
digit
micrograph
per
pixel
use
nikon
scanner
box
individu
particl
imag
use
program
use
ctfit
program
eman
determin
ctf
paramet
flip
phase
construct
initi
model
eman
use
assign
view
refin
eman
assum
icosahedr
symmetri
number
particl
incorpor
final
reconstruct
give
final
resolut
base
fourier
shell
correl
threshold
mix
vlp
equival
approxim
normal
salin
ribi
solut
sigma
adjuv
system
sigmaaldrich
per
mous
inject
femal
balbc
mice
right
left
quadricep
muscl
vlp
normal
salin
ribi
total
volum
two
time
week
dna
vaccin
inject
mice
right
left
quadricep
total
purifi
plasmid
ce
e
ce
e
suspend
normal
salin
three
time
week
group
contain
five
mice
collect
sera
spleen
day
last
inject
monkey
experi
inject
year
old
rhesu
macaqu
weigh
kg
intramuscularli
anterior
quadricep
either
vlp
ml
pb
vlp
group
ml
pb
alon
control
group
week
group
contain
six
monkey
measur
antibodi
titer
collect
blood
day
challeng
monkey
per
group
randomli
select
group
pfu
chikv
strain
week
final
immun
intraven
inject
collect
blood
measur
viremia
hour
sacrif
monkey
h
challeng
anim
experi
review
approv
anim
care
use
committe
vrc
nation
institut
allergi
infecti
diseas
http
wwwniaidnihgovvrc
accord
relev
feder
guidelin
regul
use
protein
g
hp
column
ge
healthcar
melon
gel
igg
purif
kit
pierc
antibodi
purif
dialyz
purifi
igg
three
time
pb
administ
mg
purifi
igg
approxim
serum
recipi
mous
tail
vein
inject
h
challeng
challeng
consist
pfu
chikv
strain
administ
intraderm
inject
result
express
mean
sem
analyz
data
unpair
twotail
test
prism
addit
method
describ
supplementari
method
refer
web
version
pubm
central
supplementari
materi
fig
see
also
ref
white
triangl
mark
boundari
icosahedr
asymmetr
unit
number
show
posit
icosahedr
axe
limit
asymmetr
unit
central
crosssect
cryoem
map
chikv
vlp
left
sindbi
viru
supplementari
fig
similar
orient
icosahedr
axe
well
quasithreefold
axi
shown
white
line
map
calcul
resolut
monkey
inject
pb
control
immun
vlp
challeng
intraven
pfu
chikv
strain
week
final
boost
peak
viremia
h
challeng
measur
plaqu
assay
detect
limit
pfu
per
ml
error
bar
repres
standard
error
mean
b
percentag
monocyt
monkey
white
blood
cell
measur
use
hematolog
analyz
day
challeng
chikv
error
bar
repres
standard
error
mean
unpair
twotail
test
use
statist
analysi
control
day
vs
p
vlp
day
vs
p
control
vs
vlp
day
p
c
purifi
igg
monkey
immun
vlp
immun
control
monkey
control
igg
passiv
transfer
mice
intraven
mg
total
igg
per
mous
per
group
recipi
mice
challeng
h
igg
transfer
lethal
challeng
pfu
intraderm
inject
viremia
mice
challeng
measur
quantit
rtpcr
limit
detect
rna
copi
per
ml
error
bar
repres
standard
error
mean
surviv
curv
mice
passiv
transfer
control
igg
chikv
immun
igg
lethal
challeng
akahata
et
al
page
